Publications

Export 15 results:
Sort by: Author [ Title  (Asc)] Type Year
[A] B C D E F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
A
Abdel Badaee, H., A. Edrees, S. Amin, M. Elamir, and G. Ragab, "Activated protein C resistance in Behcet's disease", Thrombosis Journal, vol. 11, issue 1, 2013. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Abdel Badaee, H., A. Edrees, S. Amin, M. El Amir, and G. Ragab, "Activated protein C resistance in Behcet's disease.", Thrombosis journal, vol. 11, issue 1, pp. 17, 2013. Abstract

Behcet's disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most frequent. Endothelial dysfunction resulting from vascular inflammation is considered to be an important factor of thrombosis, although the endothelial injury itself cannot completely explain the hypercoagulable state of the disease because other vasculitis syndromes do not increase the risk of thrombosis. The aim of this study is to evaluate the prevalence of activated protein C resistance (APC-R) in Egyptian patients with Behcet's disease. Also, to detect hyperhomocysteinemia in selected cases (with vascular complications) to assess their relationship with thromboembolic complications. The APC resistance ratio mean in the group of patients with vascular involvement was 2.6 ± 0.8 which was less than the group with no vascular involvement 2.8 ± 0.6, with non- significant P-value (0.5). There was more incidence of ocular lesions in the group of patients with high homocysteine level than the group of patients with normal homocytsteine level with significant P-value (0.08).

Abdel Badaee, H., A. Edrees, S. Amin, M. El Amir, and G. Ragab, "Activated protein C resistance in Behcet’s disease", Thrombosis journal, vol. 11, issue 1: BioMed Central, pp. 1-5, 2013. Abstract
n/a
Cacoub, P., S. Nafa Si Ahmed, Y. Ferfar, S. N. Pol, D. Thabut, C. Hezode, L. Albric, C. Comarmond, G. Ragab, and L. Quartuccio, "All Oral Interferon-Free Antivirals for Hepatitis C Virus Cryoglobulinemia Vasculitis: A Long Term Follow up Multicenter International Study", ARTHRITIS & RHEUMATOLOGY, vol. 69: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2017. Abstract
n/a
Gaggiano, C., D. Rigante, J. Hernández-Rodríguez, A. Vitale, M. Tarsia, A. Soriano, G. Lopalco, F. Iannone, M. Abdel Jaber, R. Giacomelli, et al., "Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network", Therapeutic Advances in Musculoskeletal Disease, vol. 13: SAGE Publications Ltd, 2021. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Ragab, G., M. T. Hegazy, V. Codullo, M. Mattar, and J. Avouac, "Anticoagulation in Autoimmune Rheumatic Diseases", Precision Anticoagulation Medicine: Springer, Cham, pp. 159-179, 2020. Abstract
n/a
Ragab, G., W. Ruff, D. Pearson, H. Goubran, and M. Kriegel, "Antiphospholipid Syndrome", The Microbiome in Rheumatic Diseases and Infection: Springer, 2018.
Ragab, G., W. Ruff, D. Pearson, H. Goubran, and M. Kriegel, "Antiphospholipid Syndrome", The Microbiome in Rheumatic Diseases and Infection: Springer, pp. 305-321, 2018. Abstract
n/a
Mattar, M., H. M. A. Ahmed, and G. Ragab, "Antiphospholipid Syndrome", Precision Anticoagulation Medicine: Springer, Cham, pp. 181-201, 2020. Abstract
n/a
Ragab, G., W. Ruff, D. Pearson, H. Goubran, and M. Kriegel, "Antiphospholipid syndrome", The Microbiome in Rheumatic Diseases and Infection: Springer International Publishing, pp. 305 - 321, 2018. Abstract
n/a
El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective", Journal of Advanced Research, vol. 7, issue 3: Elsevier, pp. 391 - 402, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective.", Journal of advanced research, vol. 7, issue 3, pp. 391-402, 2016 May. Abstract

Egypt, the single country with highest incidence of HCV infection in the world, has embarked on a government-sponsored mass treatment program using several combinations of DAAs. Recognizing the importance of extrahepatic manifestations, independently of the hepatic, a subcommittee was assigned to develop national guidelines for respective prioritizing indications and protocols. It evaluated the benefit of treating patients with different extrahepatic manifestations, and reviewed relevant clinical trials and guidelines concerning DAA combinations available in Egypt. The latter included Sofosbuvir plus either peg-interferon, Simeprevir, Ledipasvir or daclatasvir, and the Viekera family comprising paritaprevir/ritonavir + ombitasvir with (GT-1) or without (GT-4) Dasabuvir. Any of these protocols may be used with or without Ribavirin according to indication. A blueprint was subjected to peer debate in dedicated workshops in two national meetings and subsequently to an online professional review, eventually leading to a final report that was adopted by the health authorities. Seven compelling and 10 optional indications were identified for treating patients with predominantly extrahepatic manifestations. The former include kidney disease at different stages, cryoglobulinemic vasculitis and non-Hodgkin lymphoma. Selected treatment protocols, were encoded and their use was prioritized on the basis of evidence of efficacy and safety. We concluded that any of the studied protocols may be used, preferably with ribavirin, for 12-week treatment in all patients with extrahepatic manifestations without cirrhosis and with eGFR above 30 ml/min/1.73 sqm. Ribavirin should be included in protocols for treating patients with compensated cirrhosis. Daclatasvir-based protocols are recommended for decompensated cirrhosis, while the Viekera family is recommended in patients with eGFR < 30 ml/min/1.73 sqm, including those on dialysis. In kidney-transplanted patents, caution is due to avoidance of the pharmacokinetic interaction with the Cytochrome-P450 enzyme system, in-between immunosuppressive agents and most DAAs, particularly the Viekera family.

El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations–An Egyptian perspective", Journal of advanced research, vol. 7, issue 3: Elsevier, pp. 391-402, 2016. Abstract
n/a
Pusiol, A., F. Marzona, D. Cucchiaro, L. Castriotta, S. Usai, M. Narduzzi, C. Pilotto, I. Liguoro, R. Tosolini, and E. Passone, "Articles online first", Minerva Pediatrica, 2020. Abstract
n/a
Tourism